Menopause and hormone therapy in the 21st century: why promote transdermal estradiol and progesterone?
Pierre-Yves Scarabin, Marianne Canonico, Geneviève Plu-Bureau, Emmanuel Oger

To cite this version:
Pierre-Yves Scarabin, Marianne Canonico, Geneviève Plu-Bureau, Emmanuel Oger. Menopause and hormone therapy in the 21st century: why promote transdermal estradiol and progesterone?. Heart, 2020, 106 (16), pp.1278.1-1278. 10.1136/heartjnl-2020-316907. hal-02862267

HAL Id: hal-02862267
https://univ-rennes.hal.science/hal-02862267
Submitted on 7 Jul 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.
Menopause and hormone therapy in the 21st century: why promote transdermal estradiol and progesterone?

In their editorial, Gersh and Lavie describe the many ways that estradiol impacts cardiovascular health. In addition, the authors rightly question the findings of the Women’s Health Initiative among menopausal women using hormone therapy. Importantly, they emphasise the need for using the most physiological human-identical transdermal estradiol combined with natural progesterone. However, no information is given on both the biological rationale and the expected benefits of transdermal oestrogens compared with oral oestrogens. Oral but not transdermal oestrogens result in a hepatic first-pass effect that may induce reversible prothrombotic changes in haemostatic variables, including resistance to activated protein C (figure 1). Thrombotic process plays a critical role in the development of both venous and arterial diseases. European studies have clearly shown the advantage of transdermal oestrogens with respect to the risk of venous thromboembolism and probably also stroke. The type of progestogens has also emerged as an important determinant of thrombosis. Progesterone has no effect on blood coagulation, and it is the safest progestogen with respect to thrombosis. Since thrombosis is one main serious adverse effect of hormone therapy, women should be encouraged to use transdermal oestrogens combined with progesterone.

REFERENCES

Provenance and peer review Not commissioned; internally peer reviewed.
Patient consent for publication Not required.
Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.

Figure 1  Caption.